Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis
作者： Renandro de Carvalho Reis , Kelson James Almeida , Luciano da Silva Lopes , Cíntia Maria de Melo Mendes , Edson Bor-Seng-Shu
DOI: 10.1016/J.YEBEH.2019.106635
关键词:
摘要: Abstract This paper aimed to systematically examine the efficacy and adverse event (AE) profile of cannabidiol medicinal cannabis by analyzing qualitative meta-analytic data. We used terms (“Cannabidiol” OR “Cannabis”) AND “Epilepsy” (“Treatment” “Therapeutics”) as keywords retrieve studies indexed on PubMed, ScienceDirect, CENTRAL databases. The inclusion criteria were follows: clinical with a longitudinal observational design intervention using cannabinoid derivatives, especially cannabis, whereby some results involved frequency epileptic seizures. Cochrane Collaboration's Review Manager software (RevMan 5.1.6) for meta-analysis dichotomized articles confidence interval 95%. From 236 articles, we selected 16 descriptive analysis; only 4 meta-analysis. According results, statistically meaningful effect compared placebo was observed (p
elsevier.com
sci-hub.se 参考文章(60)
Daniel Friedman, Orrin Devinsky, Cannabinoids in the Treatment of Epilepsy The New England Journal of Medicine. ,vol. 373, pp. 1048- 1058 ,(2015) , 10.1056/NEJMRA1407304
Alberto Verrotti, Claudia D’Egidio, Angelika Mohn, Giangennaro Coppola, Pasquale Parisi, Francesco Chiarelli, Antiepileptic drugs, sex hormones, and PCOS. Epilepsia. ,vol. 52, pp. 199- 211 ,(2010) , 10.1111/J.1528-1167.2010.02897.X
Patrick Kwan, Alexis Arzimanoglou, Anne T. Berg, Martin J. Brodie, W. Allen Hauser, Gary Mathern, Solomon L. Moshé, Emilio Perucca, Samuel Wiebe, Jacqueline French, Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. ,vol. 51, pp. 1069- 1077 ,(2009) , 10.1111/J.1528-1167.2009.02397.X
Patrick Kwan, Martin J. Brodie, Early Identification of Refractory Epilepsy New England Journal of Medicine. ,vol. 342, pp. 314- 319 ,(2000) , 10.1056/NEJM200002033420503
M. Ruth Pazos, Nagat Mohammed, Hector Lafuente, Martin Santos, Eva Martínez-Pinilla, Estefania Moreno, Elsa Valdizan, Julián Romero, Angel Pazos, Rafael Franco, Cecilia J. Hillard, Francisco J. Alvarez, Jose Martínez-Orgado, Mechanisms of cannabidiol neuroprotection in hypoxic–ischemic newborn pigs: Role of 5HT1A and CB2 receptors Neuropharmacology. ,vol. 71, pp. 282- 291 ,(2013) , 10.1016/J.NEUROPHARM.2013.03.027
G. Zaccara, P.F. Gangemi, M. Cincotta, Central nervous system adverse effects of new antiepileptic drugs: A meta-analysis of placebo-controlled studies Seizure-european Journal of Epilepsy. ,vol. 17, pp. 405- 421 ,(2008) , 10.1016/J.SEIZURE.2007.12.003
RALPH KARLER, STUART A. TURKANIS, The Cannabinoids as Potential Antiepileptics The Journal of Clinical Pharmacology. ,vol. 21, ,(1981) , 10.1002/J.1552-4604.1981.TB02624.X
Chad Cook, Joshua Cleland, Eric Hegedus, Alexis Wright, Mark Hancock, The creation of the diagnostic accuracy quality scale (DAQS) Journal of Manual & Manipulative Therapy. ,vol. 22, pp. 90- 96 ,(2014) , 10.1179/2042618613Y.0000000032
Svein I. Johannessen, Cecilie Johannessen Landmark, Antiepileptic Drug Interactions - Principles and Clinical Implications Current Neuropharmacology. ,vol. 8, pp. 254- 267 ,(2010) , 10.2174/157015910792246254
Rongrong Jiang, Satoshi Yamaori, Shuso Takeda, Ikuo Yamamoto, Kazuhito Watanabe, Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences. ,vol. 89, pp. 165- 170 ,(2011) , 10.1016/J.LFS.2011.05.018